Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety, Tolerability, Efficacy, Pharmacokinetics Profile and Immunogenicity of HS-20117 in Combination With Other Drugs in Advanced Solid Tumors, a Phase Ib Clinical Trial

NCT06621563 is registered in ClinicalTrials.gov with Hansoh BioMedical R&D Company as lead sponsor.

NCT NCT06621563
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06621563 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety, Tolerability, Efficacy, Pharmacokinetics Profile and Immunogenicity of HS-20117 in Combination With Other Drugs in Advanced Solid Tumors, a Phase Ib Clinical Trial
Lead sponsor
Hansoh BioMedical R&D Company
Phase
Phase 1
Overall status
Recruiting
Start date
December 14, 2024
Completion date
December 1, 2026
Enrollment
780 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer, non-small cell lung cancer, solid tumors